3D Bioprinted in vitro metastatic models via reconstruction of tumor microenvironments
Open accessAbstract
The development of 3D in vitro models capable of recapitulating native tumor microenvironments could improve the translatability of potential anticancer drugs and treatments. Here, 3D bioprinting techniques are used to build tumor constructs via precise placement of living cells, functional biomaterials, and programmable release capsules. This enables the spatiotemporal control of signaling molecular gradients, thereby dynamically modulating cellular behaviors at a local level. Vascularized tumor models are created to mimic key steps of cancer dissemination (invasion, intravasation, and angiogenesis), based on guided migration of tumor cells and endothelial cells in the context of stromal cells and growth factors. The utility of the metastatic models for drug screening is demonstrated by evaluating the anticancer efficacy of immunotoxins. These 3D vascularized tumor tissues provide a proof‐of‐concept platform to i) fundamentally explore the molecular mechanisms of tumor progression and metastasis, and ii) preclinically identify therapeutic agents and screen anticancer drugs.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Bioprinted models were assembled with tumor cells, an endothelialized microchannel, a fibroblast-laden natural hydrogel, and 3D printed programmable release capsules.
“Bioprinted models were assembled with tumor cells, an endothelialized microchannel, a fi broblast-laden natural hydrogel, and 3D printed programmable release capsules (triggered by”
From 3D In Vitro Model (R)evolution: Unveiling Tumor–Stroma Interactions (2021) · cites this paper as [39]
Bioprinted 3D tumor constructs were developed to recapitulate the TME that leads to metastatic dissemination of lung cancer.
“As a representative example, bioprinted 3D tumor constructs were developed to recapitulate the TME that leads to metastatic dissemination of lung cancer [39].”
From 3D In Vitro Model (R)evolution: Unveiling Tumor–Stroma Interactions (2021) · cites this paper as [39]
EGF released from capsules actively promotes proliferation of lung cancer cells and guides their migration.
“the results showed that epidermal growth factor (EGF) released from the capsules actively promotes the proliferation of lung cancer cells and guides their migration [39].”
From 3D In Vitro Model (R)evolution: Unveiling Tumor–Stroma Interactions (2021) · cites this paper as [39]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 59 · Cited by 262
Research works printed but not linked: 1
- [22]Roussos ET, Condeelis JS, Patsialou A, Nat. Rev. Cancer 2011, 11, 573. 21779009 PMC4030706
- Authors
- Meng, F., Meyer, C. M., Joung, D., Vallera, D. A., McAlpine, M. C., & Panoskaltsis‐Mortari, A.
- Affiliations
- University of Minnesota (US)
- Corresponding author
- McAlpine, Michael C.
- Panoskaltsis‐Mortari, Angela
- Venue
- Advanced Materials
- Publisher
- Wiley
- Published
- 2019-01-21
- Volume
- 31
- Issue
- 10
- Pages
- e1806899-e1806899
- ISSN
- 0935-9648 (ISSN-L)
- 1521-4095
- PMC
- PMC6996245
- OpenAlex
- W2912567037
- Cited by
- 262
- References
- 59
- Citations by year
- 2026: 21 · 2025: 29 · 2024: 32 · 2023: 48 · 2022: 44 · 2021: 45 · 2020: 35 · 2019: 8
- FWCI
- 11.62
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Advanced Materials (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Biomedical Imaging and Bioengineering (1R21EB022830, 1DP2EB020537)
- Topics
- Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Cellular Mechanics and Interactions
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- 3D bioprinting, metastasis model, tumor invasion, intravasation, angiogenesis, endothelial cell migration, stromal cells, growth factor gradients, anticancer drug screening, immunotoxins, tumor progression
- MeSH terms
- Drug Screening Assays, Antitumor, Humans, Neoplasms, Tissue Engineering, Biomimetics, Tissue Scaffolds, Tumor Microenvironment, Printing, Three-Dimensional
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
